Mylan N.V. shares had a trading volume of 19,856K ... Shares are trading at $32.03 which is a tad under $32.33, the stock’s 50 day moving average and which is well below the 200 day moving average of $37.58. The 50 day moving …
EpiPen continues to be a major overhang for the stock. Generics facing shrinking margins and price erosion will not be good for profit. FDA interfering on generic competitiveness will be a huge blow for the company. Recently, Mylan (MYL) …
Mylan’s stock has fallen 16.7% year to date compared with the industry’s decline of 14.9%. Mylan’s second-quarter results were dismal as the company missed on …
Mylan dropped 4% to $29.63 today, while the S&P 500 rose 1% to 2,465.84. In a note released on Aug. 9 following Mylan's earnings, Cowen analyst Ken …
Mylan Faces 3-Month Delay in Herceptin Biosimilar Decision: Mylan NV (MYL - …
Mylan N.V. says that it is now expecting earnings per share for the full year of 2017 to range from $4.30 to $4.70 on revenue between $11.5 billion and $12.5 billion. This is bad news for MYL stock, as Wall Street is looking for earnings …
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports. Mylan's stock plunged after the maker of Epi …
In fact, Mylan's stock tumbled 29% in 2016 in the wake of outrage over its EpiPen price tactics. Yet its top talent – Chair Coury and CEO Heather Bresch – were rewarded with shocking salaries. Bresch was paid $13.8 million in 2016, down …
Aug. 9 (UPI) — Pharmaceutical maker Mylan NV announced it would not launch any new medications to the U.S. market in 2017. The company faces regulatory uncertainty in the rollout of two new products: generic versions of Teva …